Q-omics provides the consensus-scored FOXK1 profile across patient tissues and cancer cell-line models. FOXK1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FOXK1 is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, FOXK1 protein abundance shows 25,553 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, COAD, and GBM as cancer lineages where FOXK1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FOXK1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FOXK1 survival associations across molecular data types. FOXK1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FOXK1 RNA expression–survival associations across cancer types. High FOXK1 expression shows unfavorable associations in ACC, LIHC, OV, MESO and UVM, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FOXK1 RNA expression.
This table summarizes FOXK1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for FOXK1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FOXK1 shows higher tumor expression in COAD, HNSC, LIHC, KICH, LUSC and KIRC. The COAD box plot shows higher FOXK1 RNA expression in tumor versus normal tissue (log2 FC = +1.123, t-test p < 0.001).
This table shows molecular features associated with FOXK1 in patient tissues and cancer cell lines. In patient samples, FOXK1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FOXK1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and OVARY.
